ICICI Securities has set a target price of ₹1,275 for Max Healthcare following strong Q1 revenue growth of 16.7%. While analysts remain optimistic about the hospital chain’s expansion, the company faces short-term pressure from rising debt, margin compression, and the discontinuation of certain chemotherapy drug sales.
ICICI Securities has issued a 'Buy' recommendation for Max Healthcare Institute, setting a target price of ₹1,275. This update follows the company’s recent first-quarter results for the 2027 fiscal year, where it reported a 16.7% year-on-year increase in revenue, reaching ₹2,366 crore. The brokerage’s outlook is driven by the company’s ongoing focus on scaling up its hospital bed capacity and improving average earnings per patient.
Max Healthcare continues to aggressively expand its footprint, with operational bed capacity reaching 5,379 beds as of June 2026. The company’s management has set a long-term goal to reach 10,000 beds by the 2030 fiscal year. This expansion is supported by recent strategic moves, such as the acquisition of a 58.28% stake in Kalinga Hospital in May 2026, which is expected to help the company grow its presence in new regions.
However, the company’s growth trajectory currently faces certain headwinds. The most notable challenge is the discontinuation of high-value chemotherapy drugs previously supplied to institutional patients, which has impacted revenue and profit margins. To offset this, the company is implementing price increases for insurance-based patients and utilizing government reimbursement schemes, with management expecting the negative impact to fade by the third quarter of this fiscal year.
Investors should also monitor the impact of aggressive expansion on the company's financial health. The company’s net debt has increased to ₹2,384 crore as of June 30, 2026, compared to ₹1,908 crore at the end of the previous fiscal year. This rise in debt, alongside integration costs from new acquisitions and the ramp-up phase of newly commissioned beds, has led to some margin pressure, with the operating EBITDA margin reported at 24.8% for the quarter.
While the brokerage remains positive about the long-term potential, the combination of higher depreciation, increased finance costs, and the need to successfully integrate new facilities means that consistent execution is vital. The key monitorable for the coming quarters will be how effectively Max Healthcare manages its debt levels while maintaining stable profit margins during this heavy phase of capital spending.